Latest news
How Investors May Respond To Nurix Therapeutics (NRIX) Advancing Bexobrutideg Into Registrational Phase 3 With Roche - simplywall.stsimplywall.st · Wed, 05 Aug 2026 20:38:08 GMT73 primary schools to hold ballots for Phase 2C of P1 registration - The Straits TimesThe Straits Times · Wed, 05 Aug 2026 10:55:00 GMTPrimary 1 registration: Nearly half of all primary schools oversubscribed in Phase 2C - channelnewsasia.comchannelnewsasia.com · Wed, 05 Aug 2026 10:10:00 GMTOpus Genetics Completes Enrollment in Phase 3 Trial of Gene Therapy for Inherited Retinal Disease - Eyewire+Eyewire+ · Tue, 04 Aug 2026 13:06:40 GMTBlossomHill Therapeutics prices USD 125m IPO to advance EGFR inhibitor BH-30643 in lung cancer - AllSciAllSci · Tue, 04 Aug 2026 11:11:47 GMTOpus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Tue, 04 Aug 2026 07:38:27 GMTNurix Phase 3 Trial Tests Bexobrutideg Against CLL Standard of Care - stocktitan.netstocktitan.net · Tue, 04 Aug 2026 05:03:02 GMTNurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - Yahoo FinanceYahoo Finance · Tue, 04 Aug 2026 05:00:00 GMT